Friday, 21 Feb 2020

Biologic/Novel Rx

Datesort descending Type Title Save
22 Feb 2016 Social FDA has launch a CME course on biosimilars - reviews law, terminology, FDA approach to biosimilars https://t.co/5VDCzuiGNF
25 Feb 2016 Social Pfizer reveals approval & availability of once daily Xeljanz 11mg qd (=5mg bid) w/ same indications, use & monitor https://t.co/vbPsP3TpLE
25 Feb 2016 Social How to manage patients who worry, wont do & negatively inclined re:health/meds - the negative narrator in your head https://t.co/KEeVcWVedr
07 Mar 2016 Social Dermatologist Dr. Blauvelt Video on #biosimilars - discusses regulatory/safety/cost issues, substitution and access https://t.co/4W7Whmc85k
09 Mar 2016 News Tocilizumab Induces and Maintains Remission in Giant Cell Arteritis
09 Mar 2016 News Biosimilars Reviewed by Expert Panel
11 Mar 2016 Social MONARCH study shows monoRx sarilumab (IL6 inhib) beats Humira @24wk w/ ACR 20 (72 vs 58%),but neutropenia (14 vs 1%) https://t.co/4eG16hLsom
15 Mar 2016 Social 63 Actemra nonresponders switched to TNFi (41) or Orencia (22) - more TNFi achieved LDAS (CDAI<10) (64% vs 24% ABA) https://t.co/xmAuMJN4Gd
16 Mar 2016 News IL-6 Inhibition Makes News
20 Mar 2016 Social Tofacitinib meets primary endpoints in ulcerative colitis trials, achieving 16-18% remission rates https://t.co/mkWZTfz213
25 Mar 2016 Social EMA will re-review Pfizers application to license Xeljanz 5 mg bid for RA in the EU. https://t.co/vFzdpV3Kx4
01 Apr 2016 Social RT @ACRheum: ACR supports @US_FDA draft guidance on biosimilars labeling; encourages added measures to ensure safety & efficacy: https://t.…
03 Apr 2016 Social IMS Health estimates $92 billion in global sales of branded drugs & biological products will have lost patent protection between 2011 & 2015
04 Apr 2016 Social #Sjogrens metanalysis of 5 RCTs, 276pt, shows Rituximab had no effect on Schirmers, fatigue, ESSDAI & SF36 @ wk24.  https://t.co/RwyFm1lB3H
05 Apr 2016 Social RT @WIRheum: FDA approves Inflectra, a biosimilar to Remicade https://t.co/ypSrHrVzKP
06 Apr 2016 Social The newly approved biosimilar of Remicade is called Inflectra - generic name infliximab-dyyb - shouldnt that have been infliximab DIY?
11 Apr 2016 News A Rocky Start for Biosimilar Inflectra?
14 Apr 2016 News Biosimilar Reports - April 2016
15 Apr 2016 Social Tocilizumab to remain a second line treatment for polymyalgia rheumatica. More RCT needed https://t.co/yPcFI9s3CR @DrPetryna
20 Apr 2016 Blog Do's and Don'ts of Vaccination: a (Very) Brief Guide for Rheumatologists